Lucentis ranibizumab – 10mg/ml Vial 0.23ml (refrigerate)

US $2,346.00

Pack with one 0.23 ml vial x 10 mg / ml eac

Looking for a treatment that can help improve your vision? Lucentis may be just what you’re looking for! This drug is used in adults to treat several eye diseases causing vision impairment. It may also be associated with macular oedema (swelling of the centre of the retina).

Lucentis
Lucentis ranibizumab - 10mg/ml Vial 0.23ml (refrigerate) US $2,346.00
Prescription Required

Fast & Secure shipping on all orders

  • Quality & Safety Guarantee
  • Typically arrives within 3 – 5 Business days
Guaranteed Safe Checkout

Questions? Request a Call Back

About Lucentis Ranibizumab

(See detailed Medicine Prescription Information here)

Type of medication
Injection into the eye.
Assist in
Type
Prescription medication.
Treatment of
treatment of patients with wet age-related macular degeneration (WAMD), diabetic retinopathy (DR), diabetic macular edema (DME), myopic choroidal Neovascularization (mCNV), and macular edema following retinal vein occlusion (RVO).
Medicine family
(Monoclonal Antibody – cloning technique used to create unique white blood cells.
Dosage
For ophthalmic intra-vitreal injection only

LUCENTIS Ranibizumab is a prescription medicine for the treatment of patients with:

  • wet age-related macular degeneration (WAMD)
  • diabetic retinopathy (DR)
  • diabetic macular edema (DME)
  • myopic choroidal Neovascularization (mCNV)
  • macular edema following retinal vein occlusion (RVO)

Ranibizumab is branded as Lucentis and is a monoclonal antibody fragment (Fab). It is created from the same parent mouse antibody as bevacizumab. Genentech develops Ranibizumab which Novartis markets. A study has indicated that usage of Lucentis is associated with a lower risk of intestinal stomach problems and a low rate of eye-related side effects. Clinical trials’ most common side effects were conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation.

Know more about some terms in Lucentis Ranibizumab :

  • AMD or ARMD (Age-related Macular Degeneration) – The condition in which a person will have blurred or no vision in the center of the visual field. It may not result in complete blindness but will make regular life difficult.
  • Macular Edema – This may result in yellow deposits in and under the eye’s macula. The retina may thicken (edema), affecting central vision.
  • Branch Retinal Vein Occlusion – Is observed in the elderly and is caused by the occlusion of one of the branches of the central retinal vein.

What is the dosage of Lucentis Ranibizumab?

It will depend on the essential treatment the medicine is used for:

  • For Neovascular (Wet) Age-Related Macular Degeneration (AMD):
    • LUCENTIS 0.5 mg (0.05 mL) as an intravitreal injection once a month (approximately 28 days).
  • Alternate dosage is not as effective
    • Start with 3 monthly doses followed by less frequent dosing with regular assessment.
  • Start with one dose every 3 months after 4 monthly doses with periodic evaluations.
  • Macular Edema following Retinal Vein Occlusion (RVO):
    • LUCENTIS 0.5 mg (0.05 mL) as an intravitreal injection once a month (approximately 28 days).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR):
    • LUCENTIS 0.3 mg (0.05 mL) as an intravitreal injection once a month (approximately 28 days).
  • Myopic Choroidal Neovascularization (mCNV)
    • LUCENTIS 0.5 mg (0.05 mL) as an intravitreal injection once a month (about 28 days) for up to three months.

Separately packaged as a single-use prefilled syringe and for single eyes are designed to provide 0.05 mL for intravitreal injections:

  • 10 mg/mL solution (LUCENTIS 0.5 mg)
  • 6 mg/mL solution (LUCENTIS 0.3 mg)

ranibizumab

Separately packaged as a single-use glass vial designed to provide 0.05 mL for intravitreal injections:

  • 10 mg/mL solution (LUCENTIS 0.5 mg)
  • 6 mg/mL solution (LUCENTIS 0.3 mg)

ranibizumab

Warnings while using Lucentis Ranibizumab

  • Monitor patients regularly following injections.
  • Endophthalmitis and retinal detachments may occur.
  • May observe increases in intraocular pressure (IOP) during the pre-intravitreal and post-intravitreal injections.
  • May pose the risk of arterial thromboembolic events.
  • Higher risk of fatalities in patients with DME and DR at baseline were treated monthly with LUCENTIS ranibizumab compared with control.
  • Other risks are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.

How to store Lucentis Ranibizumab?

Store LUCENTIS ranibizumab in refrigerator at 2º-8ºC (36º-46ºF). DO NOT FREEZE. Always read the label and expiry date. Protect LUCENTIS ranibizumab from light and leave it in the original package under sealed condition until the time of use. Do not Freeze Lucentis ranibizumab.

Lucentis Ranibizumab Precautions:
  • Do not share prefilled syringe or vial with other people
  • Do not re-use needles
  • Visit your doctor regularly.
  • Always read the label and expiry date.
  • Only use the product if the packaging is protected.
  • Protect LUCENTIS from light and leave it in the original package under sealed condition until the time of use.
  • Do not Freeze Lucentis.
  • Keep Lucentis and associated medicines out of the reach of children.

Remember that regular physical exercise is crucial to treating diabetes or managing prediabetes, along with your diet planning, weight management, and medications. Because your cells become more responsive to insulin while you are active, your blood glucose, also known as blood sugar, can be lowered more successfully. Take your medications regularly and follow up with your healthcare specialist.

Category:

Related products